» Articles » PMID: 16686392

Suppression of Allergic Response by CpG Motif Oligodeoxynucleotide-house-dust Mite Conjugate in Animal Model of Allergic Rhinitis

Overview
Journal Am J Rhinol
Date 2006 May 12
PMID 16686392
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Although there have been many therapeutic options for allergic disease, the true allergen desensitization remains a challenging goal. The classic immunotherapy has a limited efficacy, is inconvenient, and has a risk of anaphylaxis. Recent reports revealed that immunostimulatory DNA sequences (ISS-oligdeoxynucleotide [ODN], CpG motif) act as a strong Th1 response-inducing adjuvants and that DNA-based vaccination might be an effective therapeutic option. In this study, we investigate whether ISS-ODN/Dermatophagoides farinae (Der f) conjugate has antiallergic effects in the allergic rhinitis mouse model, sensitive to house-dust mites. Der f is the most common allergen-inducing allergic rhinitis in Korea.

Methods: C57BL/6 mice were sensitized with crude extract of Der f. After injection of ISS-ODN or ISS-ODN/Der f conjugate, several parameters of allergic response were evaluated.

Results: Scratching and sneezing symptoms and eosinophilic infiltration into nasal mucosa were suppressed by injection with ISS-ODN only and ISS-ODN/Der f conjugate. Interleukin-5 level was decreased and interferon gamma level was increased in nasal lavage fluid by injection of ISS-ODN/Der f conjugate. Der f-specific immunoglobulin E was decreased by injection of ISS-ODN or Der f /ISS-ODN conjugate; however, these were not statistically significant. Transforming growth factor beta1 secreted by cultured splenocyte was increased significantly in ISS-ODN/Der f conjugate group.

Conclusion: These results suggest ISS-ODN/Der f conjugate induces an antiallergic effect and induces an increase in transforming growth factor beta1 level in the allergic rhinitis model using Der f allergen. Allergic response developed by Der f allergen could be more effectively reduced by injection with ISS-ODN/Der f conjugate than by injection with ISS-ODN only.

Citing Articles

Toll-Like Receptor Agonists as Adjuvants for Allergen Immunotherapy.

Kirtland M, Tsitoura D, Durham S, Shamji M Front Immunol. 2020; 11:599083.

PMID: 33281825 PMC: 7688745. DOI: 10.3389/fimmu.2020.599083.


Formulations for Allergen Immunotherapy in Human and Veterinary Patients: New Candidates on the Horizon.

Pali-Scholl I, DeBOER D, Alessandri C, Adel Seida A, Mueller R, Jensen-Jarolim E Front Immunol. 2020; 11:1697.

PMID: 32849594 PMC: 7417425. DOI: 10.3389/fimmu.2020.01697.


CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergies.

Hanagata N Int J Nanomedicine. 2017; 12:515-531.

PMID: 28144136 PMC: 5248940. DOI: 10.2147/IJN.S114477.


The Role of IL-17 in a Lipopolysaccharide-Induced Rhinitis Model.

Bae J, Kim J, Kim E, Mo J Allergy Asthma Immunol Res. 2017; 9(2):169-176.

PMID: 28102062 PMC: 5266111. DOI: 10.4168/aair.2017.9.2.169.


Characterization of a novel high-dose ovalbumin-induced murine model of allergic sinonasal inflammation.

Mendiola M, Tharakan A, Chen M, Asempa T, Lane A, Ramanathan Jr M Int Forum Allergy Rhinol. 2016; 6(9):964-72.

PMID: 27060366 PMC: 5012925. DOI: 10.1002/alr.21768.